Table 1

Summary of outcome measures

Adults with asthmaLong-term, low-dose macrolidesPlacebo
  • Quality-of-life measures

  • Symptom improvement/symptom score

  • Exacerbation rates

  • Hospital admission rate

  • Disease progression and changes in lung function tests

  • Mortality

  • Exercise capacity/tolerance

  • Sputum volume/colour/character and microbiological resistance/dysbiosis

  • Drug monitoring/side effects/toxicity

Adults with bronchiectasis
Adults with COPD
Adults with bronchiolitis obliterans
Adults with chronic cough
Adults with organising pneumonia
Adults with diffuse panbronchiolitis